These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19618426)

  • 21. Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle.
    Caron G; Marqueste T; Decherchi P
    PLoS One; 2015; 10(10):e0140439. PubMed ID: 26485650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of upper limb botulinum toxin injections on impairment, activity, participation, and quality of life among stroke patients.
    Caty GD; Detrembleur C; Bleyenheuft C; Deltombe T; Lejeune TM
    Stroke; 2009 Jul; 40(7):2589-91. PubMed ID: 19407231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recovery of rat muscle size but not function more than 1 year after a single botulinum toxin injection.
    Ward SR; Minamoto VB; Suzuki KP; Hulst JB; Bremner SN; Lieber RL
    Muscle Nerve; 2018 Mar; 57(3):435-441. PubMed ID: 28556093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No change in calf muscle passive stiffness after botulinum toxin injection in children with cerebral palsy.
    Alhusaini AA; Crosbie J; Shepherd RB; Dean CM; Scheinberg A
    Dev Med Child Neurol; 2011 Jun; 53(6):553-8. PubMed ID: 21574991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin A-induced muscle paralysis stimulates Hdac4 and differential miRNA expression.
    Worton LE; Gardiner EM; Kwon RY; Downey LM; Ausk BJ; Bain SD; Gross TS
    PLoS One; 2018; 13(11):e0207354. PubMed ID: 30427927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botox produces functional weakness in non-injected muscles adjacent to the target muscle.
    Yaraskavitch M; Leonard T; Herzog W
    J Biomech; 2008; 41(4):897-902. PubMed ID: 18184613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.
    Aoki KR
    Toxicon; 2001 Dec; 39(12):1815-20. PubMed ID: 11600142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacology of botulinum neurotoxin type A].
    Bigalke H
    Wien Klin Wochenschr; 2001; 113 Suppl 4():2-5. PubMed ID: 15506044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of Botulinum Toxins for Aesthetic Uses.
    Gart MS; Gutowski KA
    Clin Plast Surg; 2016 Jul; 43(3):459-71. PubMed ID: 27363760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Motor endplate-targeted botulinum toxin injections of the gracilis muscle in children with cerebral palsy.
    Van Campenhout A; Bar-On L; Desloovere K; Huenaerts C; Molenaers G
    Dev Med Child Neurol; 2015 May; 57(5):476-83. PubMed ID: 25557985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Are botulinum toxin type A preparations really the same medication? A comparison of three botulinum toxin A for variations in labelled neurological indications].
    Sławek J; Car H; Bonikowski M; Bogucki A; Koziorowski D; Potulska-Chromik A; Rudzińska M
    Neurol Neurochir Pol; 2010; 44(1):43-64. PubMed ID: 20358485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Globular chitosan prolongs the effective duration time and decreases the acute toxicity of botulinum neurotoxin after intramuscular injection in rats.
    Sergeevichev DS; Krasilnikova AA; Strelnikov AG; Fomenko VV; Salakhutdinov NF; Romanov AB; Karaskov AM; Pokushalov EA; Steinberg JS
    Toxicon; 2018 Mar; 143():90-95. PubMed ID: 29371111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contralateral weakness following botulinum toxin for poststroke spasticity.
    Thomas AM; Simpson DM
    Muscle Nerve; 2012 Sep; 46(3):443-8. PubMed ID: 22907238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells.
    Wang L; Sun Y; Yang W; Lindo P; Singh BR
    Toxicon; 2014 May; 82():52-60. PubMed ID: 24560879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
    Kutschenko A; Weisemann J; Kollewe K; Fiedler T; Alvermann S; Böselt S; Escher C; Garde N; Gingele S; Kaehler SB; Karatschai R; Krüger THC; Sikorra S; Tacik P; Wegner F; Wollmann J; Bigalke H; Wohlfarth K; Rummel A
    Clin Neurophysiol; 2019 Jun; 130(6):1066-1073. PubMed ID: 30871800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.
    Lorenzano C; Bagnato S; Gilio F; Fabbrini G; Berardelli A
    Neurotox Res; 2006 Apr; 9(2-3):141-4. PubMed ID: 16785111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing two botulinum toxin type A formulations using manufacturers' product summaries.
    Wenzel R; Jones D; Borrego JA
    J Clin Pharm Ther; 2007 Aug; 32(4):387-402. PubMed ID: 17635341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
    Zhang X; Strassman AM; Novack V; Brin MF; Burstein R
    Cephalalgia; 2016 Aug; 36(9):875-86. PubMed ID: 26984967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.